2 doses of S 90098 (1 and 2mg/day), sublingual formulation for depression
This study is completed in France, in Finland, in Czechia, .... It is testing 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for depression.
In France
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study is completed in France, in Finland, in Czechia, .... It is testing 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for depression.
In FranceThis study is completed in Slovakia, in Bulgaria, and in Finland. It is testing 3 dose regimens of agomelatine (10, 25, 25-50 mg) for depression.
In SlovakiaThis study is completed in France, in Finland, in Czechia, .... 5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, for depression.
In FinlandThis study is completed in Germany, in Czechia, in Hungary, .... It is testing 3 doses of S 47445 for depression.
In GermanyThis study is completed. It is testing Long Acting Anti-Psychotic for schizophrenia.
Location not clearly listedThis study is completed. It is testing A-prexa Compared to Zyprexa for schizophrenia.
Location not clearly listedThis study is completed in the United States, in Canada, in Bulgaria, .... It is testing pimavanserin for schizophrenia.
Multiple locations, including PhoenixThis study is completed in Finland. It is testing Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for anxiety.
In FinlandThis study is completed in Austria, in the Netherlands, in Spain, .... It is testing agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, for Bipolarity.
In AustriaThis study was terminated in Slovakia and in Czechia. It is testing agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for anxiety.
In SlovakiaThis study is completed in Finland, in Czechia, and in Slovakia. It is testing agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for anxiety.
In FinlandThis study is completed in Czechia, in Germany, in Hungary, .... It is testing agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for Anxiety.
In Czech RepublicHopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.